BRAF and cutaneous melanoma: In the skin cutaneous melanoma (SKCM) dataset,[29] we observed that dabrafenib achieved a higher predictive ranking in the sample with the BRAF V600E mutation (GSM6022253) and a slightly lower predictive performance in the sample with the BRAF R178* mutation (GSM6022255) (Figure S8B, Supporting Information).